



ATF Group (PDF) Limited

| | |
|-----------------|-------------------------|
| COMPANY NAME | ATF Group (PDF) Limited |
| SECTOR | Diagnostic IT |
| YR. ESTABLISHED | 2003 |
| BUSINESS STAGE | Commercial |
| LOCATION | Melbourne |
| SEEKING | Capital Raising |

Executive Summary

ATF is a pooled development fund which invests in diagnostic IT technologies. Its principal investment is Evivar Medical Pty Ltd (Evivar).

Hepatitis B (HBV) is a modern epidemic with over 2 billion people infected (1 in 12) and 360 million suffering Chronic Hepatitis B (CHB). It is not curable and patients require lifelong expensive antiviral therapy. Like many infectious diseases HBV mutates in response to drug treatments.


Evivar delivers real time, predictive, online assistance and guidance to clinicians treating patients suffering from HBV, enabling them to select the right medication at the right time for their patients. The ultimate result is an increase in the health and longevity of life for patients and a reduction in overall HBV treatment costs.

SeqHepB diagnostic system (SHB): SeqHepB is a unique viral genomics sequence analysis program that is linked to its proprietary HBV genomic and phenotypic database which is the world's most comprehensive.

From a simple blood sample the SeqHepB diagnostic system predicts which antiviral therapy is optimal for that patient.

Competitive Advantages

- **World-Class Inventor:** SHB was developed and continues to be monitored by Professor Stephen Locarnini who is recognised globally as a leading expert in HBV and antiviral resistance.
- **No competitors:** there is no other system of this type with most global diagnostic efforts going into HIV even though there are only 33 million people infected with HIV globally.
- **Market model:** Evivar has selected a ubiquitous, non-exclusive licensing model enabling it to rapidly secure global and regional diagnostic leaders as their licensing partners along the value chain (as shown in image 1.a.)
- **Patent Protected:** Evivar has uniquely patented ten patent families for the multitude of viral mutations that occur within the HBV genome. The strength of the patents has been tested by our licensees.



Key Investment Highlights

- **Development Status:** the SeqHep B system is clinically proven with all regulatory processes completed. ATF expects this will be the final fund raising round. Investors entering now are in the final stage of investment which follows approximately \$12M investment to date.
- **Securing the first licensees:** key licensing agreements have been secured with Abbott Molecular a leading global diagnostic company and LabCorp & Quest; the two largest USA clinical laboratory networks.
- **Results:** Processed over 12,000 patients in 2009 with a significant volume now coming on stream. The Company should be cash positive by mid 2011.
- **Marketing Alliance:** secured with Advanced Biological Laboratories (ABL) a European based company which has a predictive tool for HIV; offering the clinician a wider blood-borne disease solution, particularly for HIV/HBV co-infected sufferers. The complimentary science, technology, IP protection, market positions and competencies provide a springboard for both businesses to accelerate their growth with reduced cost structures.
- **Development:** Now developing a SeqHepC diagnostic system for Hepatitis C (HCV), Ultra Deep Sequencing (UDS) data platform that is 500x more detailed analysis and exploring co-infection along with other blood-borne diseases.






Image 1.a.



Corporate Structure

- Previous Investment: few significant investors of Melbourne Health and individuals with a number of smaller investors.
- Pooled Development Fund (PDF): ATF is a non listed public company which, as a registered pooled development fund enjoys significant tax breaks at both a corporate and shareholder level. There is no capital gains tax applicable on the sale by investors of their ATF shares.
- Ordinary Shares on offer: rank equal with existing ordinary issued shares.
- Investee companies: Evivar will become a wholly owned subsidiary of ATF Group.

Board & Management:

Dr. Raymond Schinazi - Phd Science Chair

Leading global researcher and founder of companies in virology and drug discovery including Pharmasset Inc., Triangle Pharmaceuticals, Idenix Pharmaceuticals and RFS Pharma LLC. Published over 420 peer reviewed papers and seven books and holds more than 70 US patents.

Jon Lamb Deputy Chair

Formerly youngest CEO with Beecham in New Zealand at 30. Joined Beecham's marketing division working in South Africa, London, Australia and New Zealand. Brings a wealth of over thirty years international experience in the pharmaceutical and bio-medical arena ranging from private start up companies to multinational public corporations.

JA Wigginton Company Secretary and Director

Is a qualified accountant with over 26 years experience in the banking and stockbroking industry, both in Australia and overseas.

B Romanin - B App Sci. and Grad Dip Marketing Director

Extensive commercial expertise in sales and marketing, technology licensing and partnership management. Working for almost a decade in the USA with Chiron and Novartis in diagnostics in the areas of Infectious Diseases.

Exit Strategy

- Trade Sale: ATF will be looking to commence a trade sale process for Evivar in the second half of 2011.
- China: ATF will be seeking to expand the Evivar business into the world's largest HBV market with an estimated 170 million chronically infected.
- Targeted Purchasers: Analysis has identified medical (global pharmaceutical companies and diagnostic companies) and software (healthcare IT service providers and global software companies) where Evivar's offering aligns to their growth strategies.

Further Information:

To learn more about this opportunity, including downloading a Prospectus, go to

www.wholesaleinvestor.com.au

click on View Investment opportunities and search for ATF Group (PDF) Limited.